Does Intellia Therapeutics Inc (NTLA) Stock Beat its Rivals in Biotechnology?

Monday, June 1, 2020 10:01 AM | InvestorsObserver Analysts

Intellia Therapeutics Inc (NTLA) is around the top of the Biotechnology industry according to InvestorsObserver. NTLA received an overall rating of 74, which means that it scores higher than 74 percent of all stocks. Intellia Therapeutics Inc also achieved a score of 77 in the Biotechnology industry, putting it above 77 percent of Biotechnology stocks. Biotechnology is ranked 8 out of the 148 industries.

Overall Score - 74
NTLA has an Overall Score of 74. Find out what this means to you and get the rest of the rankings on NTLA!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 74 would rank higher than 74 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Intellia Therapeutics Inc Stock Today?

Intellia Therapeutics Inc (NTLA) stock is higher by 10.66% while the S&P 500 is lower by -0.03% as of 9:59 AM on Monday, Jun 1. NTLA has risen $1.87 from the previous closing price of $17.51 on volume of 309,845 shares. Over the past year the S&P 500 has gained 10.89% while NTLA has risen 36.00%. NTLA lost -$2.25 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Related Companies